WO2004022717A3 - Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen - Google Patents

Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen Download PDF

Info

Publication number
WO2004022717A3
WO2004022717A3 PCT/US2003/027976 US0327976W WO2004022717A3 WO 2004022717 A3 WO2004022717 A3 WO 2004022717A3 US 0327976 W US0327976 W US 0327976W WO 2004022717 A3 WO2004022717 A3 WO 2004022717A3
Authority
WO
WIPO (PCT)
Prior art keywords
col
antibody
humanized col
humanized
carcinoembryonic antigen
Prior art date
Application number
PCT/US2003/027976
Other languages
French (fr)
Other versions
WO2004022717A2 (en
Inventor
Syed V S Kashmiri
Jeffrey Schlom
Eduardo A Padlan
Original Assignee
Us Gov Health & Human Serv
Syed V S Kashmiri
Jeffrey Schlom
Eduardo A Padlan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Syed V S Kashmiri, Jeffrey Schlom, Eduardo A Padlan filed Critical Us Gov Health & Human Serv
Priority to AU2003270369A priority Critical patent/AU2003270369A1/en
Publication of WO2004022717A2 publication Critical patent/WO2004022717A2/en
Publication of WO2004022717A3 publication Critical patent/WO2004022717A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Abstract

The present disclosure provides humanized COL-1 monoclonal antibodies that are minimally immunogenic and that retain carcinoembryonic antigen binding affinity. In one embodiment, a humanized COL-1 antibody includes an amino acid substitution at position 61 in a heavy chain complementarity determining region 2 of the murine COL-1 antibody. In another embodiment, a humanized COL-1 antibody includes an amino acid substitution at position 24, 25, and 27 in a light chain complementarity determining region 1 of the murine COL-1 antibody. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a tumor in a subject. Also disclosed is a kit including the humanized COL-1 antibody described herein.
PCT/US2003/027976 2002-09-05 2003-09-05 Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen WO2004022717A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003270369A AU2003270369A1 (en) 2002-09-05 2003-09-05 Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40870302P 2002-09-05 2002-09-05
US60/408,703 2002-09-05

Publications (2)

Publication Number Publication Date
WO2004022717A2 WO2004022717A2 (en) 2004-03-18
WO2004022717A3 true WO2004022717A3 (en) 2004-09-02

Family

ID=31978660

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/027976 WO2004022717A2 (en) 2002-09-05 2003-09-05 Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen

Country Status (2)

Country Link
AU (1) AU2003270369A1 (en)
WO (1) WO2004022717A2 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7973136B2 (en) 2005-10-06 2011-07-05 Xencor, Inc. Optimized anti-CD30 antibodies
US8039592B2 (en) 2002-09-27 2011-10-18 Xencor, Inc. Optimized Fc variants and methods for their generation
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US8124731B2 (en) 2002-03-01 2012-02-28 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8318907B2 (en) 2004-11-12 2012-11-27 Xencor, Inc. Fc variants with altered binding to FcRn
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
US8524867B2 (en) 2006-08-14 2013-09-03 Xencor, Inc. Optimized antibodies that target CD19
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US9040041B2 (en) 2005-10-03 2015-05-26 Xencor, Inc. Modified FC molecules
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US9475881B2 (en) 2010-01-19 2016-10-25 Xencor, Inc. Antibody variants with enhanced complement activity

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005112564A2 (en) * 2004-04-15 2005-12-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Germline and sequence variants of humanized antibodies and methods of making and using them
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
AU2005322869B2 (en) 2004-12-30 2011-05-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Framework residue substituted humanized COL-1 antibodies and their use
WO2007090596A1 (en) * 2006-02-06 2007-08-16 Medizinische Universität Wien Vaccine and antigen mimotopes against cancerous diseases associated with the carcinoembryonic antigen cea
SI2808343T1 (en) 2007-12-26 2019-10-30 Xencor Inc Fc variants with altered binding to FcRn
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333405B1 (en) * 1996-10-31 2001-12-25 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333405B1 (en) * 1996-10-31 2001-12-25 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KASS E.S. ET AL: "Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer", CANCER RESEARCH, vol. 62, 1 September 2002 (2002-09-01), pages 5049 - 5057, XP002978237 *
RABEN D. ET AL: "Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene", GENE THERAPY, vol. 3, 1996, pages 567 - 580, XP002061094 *
YU B.B. ET AL: "Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: Influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics", JOURNAL OF CLINICAL ONCOLOGY, vol. 14, no. 6, June 1996 (1996-06-01), pages 1798 - 1809, XP002978417 *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US8734791B2 (en) 2002-03-01 2014-05-27 Xencor, Inc. Optimized fc variants and methods for their generation
US8124731B2 (en) 2002-03-01 2012-02-28 Xencor, Inc. Optimized Fc variants and methods for their generation
US8809503B2 (en) 2002-09-27 2014-08-19 Xencor, Inc. Optimized Fc variants and methods for their generation
US8039592B2 (en) 2002-09-27 2011-10-18 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US9353187B2 (en) 2002-09-27 2016-05-31 Xencor, Inc. Optimized FC variants and methods for their generation
US9193798B2 (en) 2002-09-27 2015-11-24 Xencor, Inc. Optimized Fc variants and methods for their generation
US8093359B2 (en) 2002-09-27 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US8858937B2 (en) 2002-09-27 2014-10-14 Xencor, Inc. Optimized Fc variants and methods for their generation
US8383109B2 (en) 2002-09-27 2013-02-26 Xencor, Inc. Optimized Fc variants and methods for their generation
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8735545B2 (en) 2003-03-03 2014-05-27 Xencor, Inc. Fc variants having increased affinity for fcyrllc
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US8338574B2 (en) 2004-11-12 2012-12-25 Xencor, Inc. FC variants with altered binding to FCRN
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8318907B2 (en) 2004-11-12 2012-11-27 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8324351B2 (en) 2004-11-12 2012-12-04 Xencor, Inc. Fc variants with altered binding to FcRn
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8883973B2 (en) 2004-11-12 2014-11-11 Xencor, Inc. Fc variants with altered binding to FcRn
US9040041B2 (en) 2005-10-03 2015-05-26 Xencor, Inc. Modified FC molecules
US7973136B2 (en) 2005-10-06 2011-07-05 Xencor, Inc. Optimized anti-CD30 antibodies
US9574006B2 (en) 2005-10-06 2017-02-21 Xencor, Inc. Optimized anti-CD30 antibodies
US8524867B2 (en) 2006-08-14 2013-09-03 Xencor, Inc. Optimized antibodies that target CD19
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
US9475881B2 (en) 2010-01-19 2016-10-25 Xencor, Inc. Antibody variants with enhanced complement activity

Also Published As

Publication number Publication date
AU2003270369A8 (en) 2004-03-29
WO2004022717A2 (en) 2004-03-18
AU2003270369A1 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
WO2004022717A3 (en) Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen
WO2005112564A3 (en) Germline and sequence variants of humanized antibodies and methods of making and using them
NZ593068A (en) IL-18 antibody
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
NZ547157A (en) Interferon Alpha Antibodies and their uses
JP2004527212A5 (en)
HK1076128A1 (en) Humanized collagen antibodies and related methods
WO2003100008A3 (en) Neutralizing human anti-igfr antibody
WO1998050433A3 (en) Human monoclonal antibodies to epidermal growth factor receptor
WO2003068801A3 (en) Antibody variants with faster antigen association rates
EP2112166A3 (en) Human monoclonal antibodies to CTLA-4
WO2004050683A8 (en) Antibodies directed to tumor necrosis factor and uses thereof
ITRM20030601A1 (en) METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED.
GEP20074222B (en) Antibodies to cd40
WO2003057857A3 (en) Antibodies directed to pdgfd and uses thereof
WO2005003170A3 (en) Modified antibody fragments
WO2004001381A3 (en) Novel raag10 cell surface target and a family of antibodies recognizing that target
AU2001289145A1 (en) Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof
WO2002072832A3 (en) Therapeutic binding molecules
WO2004065569A3 (en) Multi-functional antibodies
WO1999003987A3 (en) Syncytial respiratory virus epitopes and antibodies comprising them, useful in diagnosis and therapy
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
DK1167389T3 (en) Antibodies to the SEMP1 protein, method of preparation thereof, and use thereof
WO2005047328A3 (en) Antibodies against secretoryleukocyte protease inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP